Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats
- 4 June 2008
- journal article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 15 (7), 508-514
- https://doi.org/10.1111/j.1365-2893.2008.00971.x
Abstract
Summary. Silymarin, a standardized extract of the milk thistle (Silybum marianum), has a long tradition as a herbal remedy, and was introduced as a hepatoprotective agent a few years ago. However, the therapeutic effects of silymarin remain undefined. Carbon tetrachloride (CCl4) is a xenobiotic used extensively to induce oxidative stress and is one of the most widely used hepatic toxins for experimental induction of liver fibrosis in the laboratory. In this study, we investigated the restoration of the CCl4‐induced hepatic fibrosis by high dose of silymarin in rats. After treatment with oil (as normal group; n = 6) or CCl4 [as model (n = 7) and therapeutic (n = 7) groups] by intragastric delivery for 8 weeks for the induction of liver fibrosis, the rats in the normal and model group were administered orally normal saline four times a week for 3 weeks whilst the therapeutic group received silymarin (200 mg/kg). The histopathological changes were observed with Masson staining. The results showed that the restoration of the CCl4‐induced damage of liver fibrosis in the therapeutic group was significantly increased as compared to that in the model group. Moreover, silymarin significantly decreased the elevation of aspartate aminotransferase (AST), alanine aminotransferase, and alkaline phosphatase in serum, and also reversed the altered expressions of α‐smooth muscle actin in liver tissue. Therefore, these findings indicated that silymarin may have the potential to increase the resolution of the CCl4‐induced liver fibrosis in rats.Keywords
This publication has 33 references indexed in Scilit:
- Lamivudine treatment in patients with chronic hepatitis B and cirrhosisExpert Opinion on Pharmacotherapy, 2006
- Resolution of Liver Fibrosis in Chronic CCl4 Administration in the Rat after Discontinuation of Treatment: Effect of Silymarin, Silibinin, Colchicine and Trimethylcolchicinic AcidBasic & Clinical Pharmacology & Toxicology, 2005
- Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in ratsJournal of Hepatology, 2004
- Management of chronic hepatitis C virus infection: a new era of disease controlInternal Medicine Journal, 2004
- Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cellsLife Sciences, 1996
- Therapeutic effect of silipide in patients with chronic hepatitis C non-responders (NRs) to interferon (IFN) treatmentJournal of Hepatology, 1994
- The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment StrategiesThe New England Journal of Medicine, 1993
- Appearance of α‐smooth‐muscle‐actin‐positive cells in hepatic fibrosisLiver International, 1991
- Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liverJournal of Hepatology, 1989
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970